Switzerland· 61225005
Temozolomid-Teva 100 mg, Kapseln
A temozolomide product containing temozolomidum, ammonii hydroxidum, registered in Switzerland by Teva Pharma AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Temozolomide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01AX03 (temozolomide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Temozolomide · ATC L01AX03
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of temozolomide costs, country by country.
Normalised to the WHO defined daily dose (65 mg), so markets compare like for like.
- Switzerland: $34.49 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Temozolomide · price per daily dose (65 mg)
USD · FX 28 Sept 2026
- IT Italy$43.87
- CH Switzerland$34.49
The record
At a glance
Swissmedic (Switzerland)- Active substance
- temozolomidum, ammonii hydroxidum
- Manufacturer
- Teva Pharma AG
- Country
- Switzerland (CH)
- ATC code
- L01AX03
- ATC class
- Temozolomide
- Defined daily dose
- 65 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806122500505 StkCHF 209.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
354 interactions on record for temozolomide.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Temozolomide · interactions on record
354 records
- 33 severe
- 103 moderate
- 16 minor
- 202 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01AX03
Temozolomide, as other registers publish it.
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- NetherlandsBlastomat 100 mg, harde capsulesZentiva k.s.
- NetherlandsBlastomat 140 mg, harde capsulesZentiva k.s.
- NetherlandsBlastomat 180 mg, harde capsulesZentiva k.s.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0a85cae-60dc-4394-ba5a-382f74c04e20 GET /v1/drugs/d0a85cae-60dc-4394-ba5a-382f74c04e20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "temozolomidum 100 mg",
"valid_from": "2011-01-01",
"limitations": null,
"galenic_form": "Kaps 100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2011-01-01",
"self_retention_pct": 10
}See everything about temozolomide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.